Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UNITED STATES: FDA Approves Hepatitis B Viral DNA Test
The first hepatitis B virus (HBV) nucleic acid test to measure the amount of viral DNA in a patient's blood has won Food and Drug Administration approval. 'The COBAS TaqMan HBV Test extracts and then amplifies sections of viral DNA from human plasma or

Toll rises to 121 in Uganda hepatitis epidemic
A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday. A diagram showing the hepatitis C virus © AFP/File KAMPALA (AFP) - The outbreak has mainly affected

Roche Molecular Diagnostics Wins FDA OK for Hepatitis B Test
A hepatitis B viral load test, developed by Roche Molecular Diagnostics in Pleasanton, was approved by the Food and Drug Administration.

UPDATES AND COMMENTARY RSS Feed

HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...

Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

table 4

Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table  4.   P100 Latency and Central Visual Sensitivity at Baseline and at the End of Interferon Treatment of Eyes With Normal Pretreatment Visual and Neurophysiological Parameters
Age (yrs) Visual Evoked Responses (msec)
Central Visual Sensitivity (db)
Baseline End-of-Rx Baseline End-of-Rx
Eyes with normal end-of-treatment P100 latency (n = 59) 47.5 ± 15.3* 117.0 ± 5.3 117.7 ± 5.2Dagger ,dagger                                  25.4 ± 0.9§, 24.5 ± 1.6#,
Eyes with abnormal end-of-treatment P100 latency (n = 15) 59.1 ± 11.0* 117.5 ± 7.1dagger ,Dagger 138.8 ± 8.7Dagger 24.4 ± 0.7Dagger ,** 23.0 ± 1.2#,**
NOTE. Group and paired comparisons are indicated by symbols representing respective P values.
Abbreviation: NS, not significant.
* P = .007 (group comparison).
dagger P = NS.
Dagger P < .0001.
§ P = .008.
#P = .002.
** P = .016.

Return To Article
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 08 Sep 2008